Alpha particles more promising than toxins?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 5, 2010, Pages 849-850

  Barbet, Jacques ^a   Chérel, Michel ^a   Chatal, Jean François ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; CALICHEAMICIN; CD33 ANTIBODY; GEMTUZUMAB OZOGAMICIN; LYMPHOCYTE ANTIBODY; MAYTANSINE; SOBLIDOTIN; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; DRUG POTENCY; DRUG TARGETING; HALF LIFE TIME; HEMATOLOGIC MALIGNANCY; HUMAN; NOTE; TREATMENT INDICATION;

ALPHA PARTICLES; IMMUNOTOXINS; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 77952095872     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1421-5     Document Type: Note

References (11)

1. SC Srivastava 1987 Investigators review potential of antibodies in cancer detection and therapy J Nucl Med 28 143 147 1:STN:280:DyaL2s7htFOqtA%3D%3D 3806217
2. DM Goldenberg SA Gaffar SJ Bennett JL Beach 1981 Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen Cancer Res 41 11 Pt 1 4354 4360 1:CAS:528: DyaL38XjtlWktQ%3D%3D 7306964
3. HE Blythman P Casellas O Gros P Gros FK Jansen F Paolucci, et al. 1981 Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells Nature 290 5802 145 146 10.1038/290145a0 1:CAS:528:DyaL3MXktlGhu7s%3D 7207595 (Pubitemid 11149690)
4. PJ Carter PD Senter 2008 Antibody-drug conjugates for cancer therapy Cancer J 14 3 154 169 10.1097/PPO.0b013e318172d704 1:CAS:528: DC%2BD1cXotlWlsLo%3D 18536555
5. R Stasi 2008 Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia Expert Opin Biol Ther 8 4 527 540 10.1517/14712598.8.4.527 1:CAS:528:DC%2BD1cXjsFWktbs%3D 18352855 (Pubitemid 351570415)
6. T Liersch J Meller B Kulle TM Behr P Markus C Langer, et al. 2005 Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results J Clin Oncol 23 27 6763 6770 10.1200/JCO.2005.18.622 1:CAS:528:DC%2BD2MXhtFWqsb7N 16170184 (Pubitemid 46190272)
7. JF Chatal L Campion F Kraeber-Bodéré S Bardet JP Vuillez B Charbonnel, et al. 2006 Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group J Clin Oncol 24 11 1705 1711 10.1200/JCO.2005.04.4917 1:CAS:528: DC%2BD28XksVKgtLc%3D 16549819 (Pubitemid 46622142)
8. RW Kozak RW Atcher OA Gansow AM Friedman JJ Hines TA Waldmann 1986 Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy Proc Natl Acad Sci U S A 83 2 474 478 10.1073/pnas.83.2.474 1:CAS:528:DyaL28Xht1Gku7k%3D 3079913
9. MR Zalutsky DD Bigner 1996 Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates Acta Oncol 35 3 373 379 10.3109/02841869609101654 1:STN:280:DyaK283nvFKrtg%3D%3D 8679269
10. GD Lewis Phillips G Li DL Dugger LM Crocker KL Parsons E Mai, et al. 2008 Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 22 9280 9290 10.1158/0008-5472.CAN-08-1776 1:CAS:528:DC%2BD1cXhtlOmt7rK 19010901
11. H Ikeda T Hideshima M Fulciniti RJ Lutz H Yasui Y Okawa, et al. 2009 The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo Clin Cancer Res 15 12 4028 4037 10.1158/1078-0432.CCR-08-2867 1:CAS:528:DC%2BD1MXntlOis7Y%3D 19509164